PLD-105
PD‑1 non‑responding solid tumors
PreclinicalActive
Key Facts
About PeLeMed
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profilePD‑1 non‑responding solid tumors
AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.
View full company profile